Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:02 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 557 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene sequencing Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Health eHeart BioBank

NCT06976502
View directory record Official record
Conditions
Heart Diseases, Cardiac Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions
Blood Draw, Tissue Collection, DNA Collection, Medical Chart Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Nov 3, 2026, 6:02 AM EST
Completed No phase listed Observational

A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia

NCT01900119
View directory record Official record
Conditions
Severe Aplastic Anemia (SAA)
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 3, 2026, 6:02 AM EST
Completed No phase listed Observational

Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

NCT07224802
View directory record Official record
Conditions
PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
EXELiM assay (qRT-PCR validation), EXELiM small RNA sequencing
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Recruiting No phase listed Observational

Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

NCT03610802
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Not yet recruiting No phase listed Observational

PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCL

NCT07829445
View directory record Official record
Conditions
LBCL, Comprehensive Genomic, Precision Treatment
Interventions
Standard of Care (SOC)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Not listed No phase listed Observational

Imaging and Omics for Cardiovascular Risk During NASA Deep Space Missions

NCT02465554
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Myocardial contrast echocardiography
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
35 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Nov 3, 2026, 6:02 AM EST
Completed No phase listed Observational

VAlidation of a Lower Cost aneUploidy scrEen

NCT03087357
View directory record Official record
Conditions
Down Syndrome, Trisomy 18, Trisomy 13
Interventions
SmartNIPT
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
2,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Nov 3, 2026, 6:02 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force

NCT03276637
View directory record Official record
Conditions
Healthy Adults, Genetic Predisposition to Disease
Interventions
Whole exome sequencing
Genetic
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Nov 3, 2026, 6:02 AM EST
Recruiting No phase listed Observational

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Bethesda, Maryland + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 3, 2026, 6:02 AM EST
Not yet recruiting Phase 3 Interventional

Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:

NCT07458230
View directory record Official record
Conditions
Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
Interventions
NGS diagnostic findings
Diagnostic Test
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Active, not recruiting Not applicable Interventional

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

NCT04108624
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Screening Phase, Discontinuation Phase
Other · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Not listed Phase 1 Interventional

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

NCT02009709
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2
Drug · Device
Lead sponsor
Robert Mack, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Nov 3, 2026, 6:02 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

NCT07266363
View directory record Official record
Conditions
ESCC
Interventions
Small RNA sequencing of exo- and cf-miRNAs, RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay), PCR-based validation (SYNERGY assay)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Completed No phase listed Observational

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

NCT07224737
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma (Icc)
Interventions
EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

NCT00102245
View directory record Official record
Conditions
Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year and older
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Nov 3, 2026, 6:02 AM EST
Completed Not applicable Interventional Results available

CLUSTER Trial for Outbreak Detection and Response

NCT04053075
View directory record Official record
Conditions
Cluster Detection
Interventions
Routine cluster detection, Enhanced cluster detection
Other
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
Not listed
Enrollment
2,905,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
82
States / cities
Riverside, California • San Jose, California • Thousand Oaks, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Nov 3, 2026, 6:02 AM EST
Not listed No phase listed Observational

POA Prospective Repository

NCT03324841
View directory record Official record
Conditions
Solid Tumor, Adult, Oncology
Interventions
Caris MI Profiling
Diagnostic Test
Lead sponsor
Caris Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Timeline
2017 – 2023
U.S. locations
11
States / cities
Scottsdale, Arizona • Tucson, Arizona • Irvine, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 3, 2026, 6:02 AM EST
Completed Phase 2 Interventional Results available

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

NCT02969837
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Completed No phase listed Observational Accepts healthy volunteers

The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

NCT03085888
View directory record Official record
Conditions
Neoplasms, Cancer
Interventions
Not listed
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
99,481 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Elk Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Nov 3, 2026, 6:02 AM EST
Active, not recruiting Phase 2 Interventional

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

NCT02756962
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Drug · Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 6:02 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Genetics of Appendix Cancer Study

NCT05734430
View directory record Official record
Conditions
Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm, Appendiceal Adenocarcinoma, Appendiceal Carcinoid Tumor, Appendiceal Neoplasm Malignant Secondary, Appendix Adenocarcinoma, Appendix Mucinous Neoplasm, Appendix Tumor, Appendix Cancer Metastatic, Appendix NET, Low-Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Adenocarcinoma
Interventions
Genetic profiling, Retrospective tissue procurement
Genetic · Other
Lead sponsor
Andreana Holowatyj, PhD, MSCI
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2034
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Nov 3, 2026, 6:02 AM EST
Not yet recruiting Not applicable Interventional

Rapid Diagnostics for Genetic Disorders in Neonates

NCT07005700
View directory record Official record
Conditions
Acid Base Disorder
Interventions
Targeted genomic sequencing
Diagnostic Test
Lead sponsor
Sharp HealthCare
Other
Eligibility
1 Day to 6 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Nov 3, 2026, 6:02 AM EST